Cardiac%20Transplantation
肌联蛋白基因截断突变致家族性扩张型心肌病的研究进展

[2]Adams JE, Abendschein DR, Jaffe AS. Biochemical markers ofmyocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation, 1993, 88: 750-763.[3] Tate JR. Troponin revisited 2008: assay performance. Clin Chem LabMed, 2008, 46: 1489-1500.[4] Zimmermann R, Baki S, Dengler TJ, et al. Troponin T release afterheart transplantation. Br Heart J, 1993, 69: 395-398.[5] Labarrere CA, Nelson DR, Cox CJ, et al. Cardiac-specific troponin Ilevels and risk of coronary artery disease and graft failure following heart transplantation. JAMA, 2000, 284: 457-464.[6] 薛莉, 王彦卿. 心肌肌钙蛋白 Ⅰ 与慢性心力衰竭. 中国循环杂志,2005, 20: 244.[7] 刘春萍, 陆慰萱, 王孟昭, 等. 急性肺血栓栓塞血浆肌钙蛋白I 的改变及其对预后的评估. 中国循环杂志, 2004, 19: 50-52.[8] Erbel C, Taskin R, Doesch A, et al. High-sensitive troponin Tmeasurements early after heart transplantation predict short-and long-term survival. Transpl Int, 2013, 26: 267-272.[9] Potapov EV, Wagner FD, Loebe M, et al. Elevated donor cardiactroponin T and procalcitonin indicate two independent mechanisms of early graft failure after heart transplantation. Int J Cardiol, 2003, 92: 163-167.[10] Riou B, Dreux S, Roche S, et al. Circulating cardiac troponin T inpotential heart transplant donors. Circulation, 1995, 92: 409-414.[11] Venkateswaran RV, Ganesh JS, Thekkudan J, et al. Donor cardiactroponin-I: a biochemical surrogate of heart function. Eur J Cardiothoracic Surg, 2009, 36: 286-292.[12] Lin KY, Sullivan P, Salam A, et al. Troponin I levels from donors肌联蛋白基因截断突变致家族性扩张型心肌病的研究进展李发有综述,范洁审校扩张型心肌病(DCM) 是一种原因不明的以心腔左心室和(或)双心室扩大、心肌收缩功能减弱为主要特征的异质性心肌病。
A B C D E治疗心力衰竭

心力衰竭分期
A期:心衰高危但是没有器质性心脏病或心力衰竭症状 (严重高血压、冠心病、有使用心脏毒性药物治疗 或酗酒史、风湿热史、心脏病家族史等) B期:有器质性心脏病但是没有心衰症状(左心室肥厚或 纤维化、左心室舒张或收缩力降低、无症状性心 瓣膜病,既往心 肌梗死)
心力衰竭分期
C期:有器质性心脏病,并且既往或目前有心衰 症状
AICD
B期患者EF≤30%、预计心功能良好状态 (NYHA1级)存活>1年最好置入ICD C期患者既往心脏骤停、Vf、VT,置入ICD作 为二级预防,也可作为一级预防 D期患者置入ICD并不降低总死亡率,已经置 入ICD者应告知选择停止除颤 AICD有可能加重心衰,生活质量下降
Assist Devices
应用时监测
低血压
有α受体阻滞作用的制剂易于发生 首剂或加量的24~48h内发生 可将ACEI或扩血管剂减量或与β-受体阻滞剂在每日不同时 间应用,一般不将利尿剂减量 常在起始治疗3~5d体重增加,如不处理,1~2周后常致心 衰恶化 告知患者,每日称体重,如有增加,应加大利尿剂剂量 与剂量成正比
液体潴留:下肢或腹部肿胀
无症状:在评估心衰以外疾病时(如心肌梗死、心律失常 或肺循环或体循环事件)发现患者有心脏扩大 或心衰证据
心力衰竭的识别及评估
心脏病性质及程度判断:
病史及体格检查 心电图及X线胸片 二维超声心动图 核素心室造影及核素心肌灌注 冠状动脉造影 判断心肌存活的方法: 多巴酚丁胺超声心动图试验 99mTc-MIBI 201TL 心肌核素显像 PET
心力衰竭早期机制
心力衰竭 射血分数↓ 左心室收缩末容量↑ 左心室舒张末容量↑ 心排血量↓
移植

移植的基本原则和步骤(九) 移植的基本原则和步骤(
环磷酰胺(cyclophosphamide) 是一种 环磷酰胺( 烷化剂,对B细胞和T细胞均有抑制作用。 烷化剂, 细胞和T细胞均有抑制作用。 皮质激素类(corticosteroids) 主要对T 皮质激素类( 主要对T 细胞和巨噬细胞起作用。 细胞和巨噬细胞起作用。 环孢素(cyclosporine) 阻止数种早期T 环孢素( 阻止数种早期T 细胞激活基因(白介素2、3、4和γ干扰素) 细胞激活基因(白介素2 干扰素) 的转录,抑制巨噬细胞产生白介素1。 的转录,抑制巨噬细胞产生白介素1
移植的基本原则和步骤(四) 移植的基本原则和步骤(
• 临床排斥反应综合征: 临床排斥反应综合征:
慢性排斥反应(chronic rejection)-是移植 慢性排斥反应( rejection)- 物功能丧失的常见原因,可发生在移植术 物功能丧失的常见原因, 后数月至数年。免疫损伤主要形式是血管 后数月至数年。 慢性排斥,临床表现为移植器官功能缓慢 慢性排斥, 减退,增加免疫抑制药物治疗常难奏效。 减退,增加免疫抑制药物治疗常难奏效。 慢性排斥致移植器官功能丧失的唯一有效 疗法是再次移植。 疗法是再次移植。
概述(四) 概述(
• 移植简史: 移植简史:
60年代放射疗法和第一代免疫抑制药 60年代放射疗法和第一代免疫抑制药 物(硫唑嘌呤、泼尼松和抗淋巴细胞血清) 硫唑嘌呤、泼尼松和抗淋巴细胞血清) 问世。 问世。 1963年Starzl首例肝移植;1966年Kelly 1963年Starzl首例肝移植;1966年 首例肝移植 等首例胰腺移植;1967年Barnard首例心脏 等首例胰腺移植;1967年Barnard首例心脏 移植。 移植。
移植的基本原则和步骤(十) 移植的基本原则和步骤(
评估心力衰竭预后几种方法的比较

评估心力衰竭预后几种方法的比较柴熙晨【摘要】心力衰竭是各种心脏疾病的终末期表现,在预后的评估方面相继有峰心肌氧耗量法、心衰生存评分、西雅图心衰模型、MUSIC风险评分等应用于临床.该文对几种心衰评分方法进行比较,分析它们各自的优势与不足,旨在找出最适合当前我国临床使用的方法.【期刊名称】《国际心血管病杂志》【年(卷),期】2010(037)003【总页数】3页(P143-145)【关键词】评分方法;心力衰竭;预后【作者】柴熙晨【作者单位】200025,上海交通大学医学院附属瑞金医院心内科【正文语种】中文1 心衰生存评分(heart failure survival score,HFSS)HFSS针对心脏供体稀缺的状况,以筛选出最合适的心脏移植受体为目的,由Aaronson等[1]在1997年提出。
模型的推导样本来自同一家医院的268例非卧床心力衰竭患者(年龄<70岁,LVEF≤40%)的80种临床特征数据。
通过应用Kaplan-Meier方法和对数秩检验,选择可能重要的单因素预测因子,再与先前研究已认可的其他重要变量一起,置于单因素和多因素Cox风险模型中分析。
为探索各变量间关系,计算了斯皮尔曼相关系数。
最终的多元比例风险生存模型包括侵入性模型(8变量)和非侵入性模型(7变量)。
侵入性模型多加入了右心导管术获取的肺毛细血管楔压(PCWP)变量,但并没有因此获得统计学上的优势。
非侵入性模型的变量(系数)包括:缺血性心肌病(0.0693),左室射血分数(-0.0464),血清钠(-0.0470),静息心率(0.022),室内传导阻滞(0.608),峰心肌氧耗量(-0.0546),平均静息血压(-0.0255)。
各变量值(有缺血性心肌病、室内传导阻滞,值为1,无则为0)乘以其系数,再求和的绝对值即为HFSS。
HFSS≥8.10,患者处于低危,无事件生存率高于预测的移植后生存率;HFSS 7.20~8.09,患者处于中危,发生结果事件(死亡或紧急移植)的风险5倍于低危;HFSS≤7.19,患者处于高危,发生结果事件的风险是低危患者的12~21倍。
疾病营养治疗指导方案:器官移植的营养治疗心脏移植

器官移植的营养治疗心脏移植The advent of solid-organ transplantation for the treatment of patients with end-stage organ failure has been one of the most exciting medical advances in the late 20th and early 21st centuries. Thousands of lives have been saved or improved by transplantation, allowing terminally ill patients to rejoin society, work productively, and have a meaningful life.The success of solid-organ transplantation is mostly due to improvements in immunosuppressive therapy, infection prophylaxis and surgical management. These advances have led to the appearance of other previously unknown complications. A major cause of long-term failure of transplanted organs is chronic rejection. A range of contributing factors has been recognised for chronic rejection. These include immunological risk factors, such as histoincompatibility, previous acute rejections, and inadequate immunosuppression, as well as non-immunological risk factors including ischaemia-reperfusion damage, hyperlipidaemia, oxidative modification of low-density lipoprotein (LDL), infectious diseases and others.随着现代外科手术的发展,器官移植给许多垂危患者带来了第2次生命,也是外科手术水平的标志。
病理英文专业词汇

1-01 脾萎缩(spleen atrophy)1-02心肌萎缩(myocardium atrophy)1-03颅骨压迫性萎缩(cranial pressure atrophy)1-04肾压迫性萎缩(kidney pressure atrophy)1-05脑压迫性萎缩(encephalic pressure atrophy)1-06 肝水变性(hepatic hydropic degeneration)1-07 肝脂肪变(hepatic fatty degeneration)1-08 纤维组织玻璃样变性(瘢痕疙瘩)(keloid)1-09 肾凝固性梗死(renal coagulative necrosis)1-10 结核干酪样坏死(caseous necrosis)1-11 液化性坏死(脑脓肿)(lliquefactive necrosis)1-12 干性坏疽(dry gangrene)1-13 湿性坏疽(坏疽性阑尾炎)(moist gangrene)1-14 皮肤溃疡(dermal ulcer)1-15 肝细胞压迫性萎缩(肝癌)(pressure atrophy of liver)1-16 肾小管上皮细胞水变性和玻璃样变性(hydropic and hyaline degeneration of renal tubular cells)1-17 脾中央动脉玻璃样变(hyaline degeneration of central arteriole of spleen)1-18 肝脂肪变性(hepatic fatty degeneration)1-19坏死细胞的形态(the morphological change of necrosis cell)1-20 肾贫血性梗死(anemic infarct of the kidney)2-01脾梗死瘢痕(splenic infarct scar)2-02 瘢痕疙瘩(keloid)2-03骨折愈合(healing of bone fracture)2-04 肉芽组织(granulation tissue)2-05 间充质干细胞(mesenchymal stem cell)2-06 骨折愈合(healing of bone fracture)3-01肝淤血(槟榔肝)(nutmeg liver)3-02脾淤血 (spleen congestion)3-03肾淤血 (kidney congestion)3-04食管静脉曲张 (esophageal varices)3-05脑出血 (cerebral hemorrhage)3-06血管内血栓 (blood vessel thrombus)3-07心房附壁血栓 (cardiac mural thrombus)3-08脾贫血性梗死 (spleen anemic infarct)3-09肾梗死瘢痕 (infartion scar of kidney )3-10肺出血性梗死 (hemorrhagic infarct of lung)3-11肠出血性梗死 (hemorrhagic infarct of intestine)3-12肺动脉栓塞 (pulmonary artery embolism)3-13肝淤血脂变 (liver fatty change)3-14肺淤血水肿 (pulmonary congestion)3-15慢性肺淤血(肺褐色硬变)(chronic pulmonary congestion) 3-16混合血栓(mixed thrombus)3-17血栓机化(thrombus organization)4-02 纤维蛋白性心包炎(fibrinous pericarditis)4-03咽喉及气管白喉(gular or tracheal diphtheria)4-04 细菌性痢疾(bacillary dysentery)4-05蜂窝织炎(阴囊)(phlegmonous inflammation)4-06 肾脓肿 (renal abscess)4-07 肝脓肿 (liver abscess)4-08 化脓性脑膜炎 (purulent meningitis)4-09 急性卡他胃炎 (acute catarrh gastritis)4-10 炭疽性脑膜炎 (anthrax meningitis)4-11 慢性胆囊炎 (chronic cholecystitis)4-12 慢性输卵管炎 (chronic salpingitis)4-13 慢性肥厚性胃炎(chronic hypertrophic gastritis)4-14 肠道慢性炎症—肠息肉 (intestinal polyp)4-15慢性心包炎 (chronic pericarditis)4-16 脾周围炎(糖衣脾)(perisplenitis)4-17慢性扁桃体炎 (chronic tonsillitis)4-18大网膜急性炎(acute inflammation of omentum)4-19鼻息肉(nasal polyp)4-20纤维蛋白性心包炎(pericarditis)4-21假膜性炎(细菌性痢疾)4-22皮下蜂窝织炎(subcutanous phlegmonous inflammation)4-23肺脓肿(pulmonary abscess)4-24肠息肉(intestinal polyp)4-25慢性胆囊炎(chronic cholecystitis)4-26肛门瘘管(anal fistula)4-27异物肉芽肿性炎(foreign body granuloma)5-01乳头状瘤(papilloma)5-02 甲状腺瘤(thyroid adenoma)5-03 乳腺纤维腺瘤(fibroadenoma of the breast)5-04 卵巢粘液性囊腺瘤(ovary mucinus cystadenoma)5-05 结肠腺瘤性息肉病5-06 皮肤鳞癌(squamous cell carcinoma of skin)5-07 食管鳞状细胞癌(squamous cell carcinoma of esophagus)5-08 阴茎鳞癌(squamous cell carcinoma of penis)5-09 乳腺腺癌(mammary adenocarcinoma)5-10 肠腺癌(intestine adenocarcinoma)5-11 肺癌(lung cancer)5-12 肺癌脑转移(brain metastasis of lung cancer)5-13 肝癌肺转移(lung metastasis of liver cancer)5-14 胰腺癌肝转移(liver metastases of pancreatic cancer)5-15 乳腺癌淋巴结转移(lymph node metastasis of breast carcinoma)5-16胃粘液癌大网膜种植转移(epiploon implantation metastasis of gastric mucinous carcinoma )5-17 纤维瘤(fibroma)5-18 脂肪瘤(lipoma)5-19 软骨瘤(chondroma)5-20 骨瘤(osteoma)5-21 子宫平滑肌瘤(fibromyoma uteri)5-22 皮下的毛细血管瘤(subcutaneous capillary hemangioma) 5-23 肝内的海绵状血管瘤(cavernous hemangioma of liver) 5-24 淋巴管瘤(lymphangioma)5-25纤维肉瘤(fibrosarcoma)5-26 骨肉瘤(osteosarcoma)5-27软骨肉瘤(chondrosarcoma)5-28脂肪肉瘤(liposarcoma)5-29神经鞘瘤 (neurinoma)5-30 黑色素瘤 (melanoma)5-31 囊性畸胎瘤(cystic teratoma)5-32 实性畸胎瘤(solid teratoma)5-33 皮肤乳头状瘤(papilloma of the skin)5-34 甲状腺腺瘤(thyroid adenoma)5-35 肠腺瘤(enteric adenoma)5-36 鳞状细胞癌(squamous cell carcinoma)5-37结肠腺癌(colonic adenocarcinoma)5-38 乳腺腺癌(mammary adenocarcinoma)5-39 淋巴结转移癌(metastasis carcinoma of the lymph nodes) 5-40 纤维瘤(fibroma)5-41 脂肪瘤(lipoma)5-42 毛细血管瘤( capillary hemangioma)5-43 纤维肉瘤 (fibrosarcoma)5-44 骨肉瘤(osteosarcoma)5-45 神经鞘瘤(neurinoma)5-46 黑色素瘤(melanoma)6-01主动脉粥样硬化 (aortic atherosclerosis)6-02脑底动脉硬化 (cerebral atherosclerosis)6-03心肌梗死 (myocardial infarction)6-04脑出血 (cerebral hemorrhage)6-05高血压之肾(kidney of hypertention)6-06高血压之心 (heart of hypertention)6-07急性风湿性心内膜炎 (acute rheumatic endocarditis)6-08 亚急性感染性心内膜炎(subacute i nfective endocarditis)6-09风湿性心脏瓣膜病——二尖瓣狭窄 (rheumatic valvular heart disease) 6-10急性克山病之心脏 (heart of acute Keshan disease)6-11慢性克山病之心脏 (heart of chronic Keshan disease)6-12主动脉粥样硬化(aortic atherosclerosis)6-13冠状动脉粥样硬化 (coronary atherosclerosis)6-14高血压之肾(kidney of hypertention)6-15风湿性心肌炎 (rheumatic myocarditis)6-16风湿性心内膜炎 (rheumatic endocarditis)6-17亚急性感染性心内膜炎 (subacute infective endocarditis)6-18 心肌梗死 (myocardial infarction)6-19 心肌病 (myocardiopathy)7-01支气管扩张(bronchiectasis)7-02肺脓肿(pulmonary abscess)7-03肺气肿(emphysema)7-04慢性肺源性心脏病(chronic pulmonary heart disease)7-05 大叶性肺炎(红色肝样变期) (lobar pneumonia, red hepatization)7-06大叶性肺炎(灰色肝样变期)(lobar pneumonia, gray hepatization)7-07小叶性肺炎 (lobular pneumonia)7-08病毒性肺炎 (viral pneumonia)7-09 硅肺(silicosis)7-10 肺癌 (lung cancer)7-11大叶性肺炎(灰色肝样变期)(lobar pneumonia, gray hepatization)7-12 支气管肺炎(bronchopneumonia)7-13间质性肺炎 (interstitial pneumonia)7-14病毒性肺炎(viral pneumonia)7-15 慢性支气管炎(chronic bronchitis)7-16 硅肺(silicosis)7-17鼻咽癌(nasopharyngeal carcinoma)7-18 肺癌(lung carcinoma)8-01 消化性溃疡病(peptic ulcer disease)8-02 急性化脓性阑尾炎(acute suppurative appendicitis)8-03 急性坏疽性阑尾炎(acute gangrenous appendicitis)8-04 慢性阑尾炎(chronic appendicitis)8-05 阑尾粘液囊肿(appendix mucocele)8-06 急性重症肝炎(急性黄色肝萎缩)(acute severe hepatitis)8-07 亚急性重症肝炎(亚急性黄色肝萎缩)(subacute severe hepatitis)8-08 门脉性肝硬化(portal cirrhosis)8-09 胆汁性肝硬化(biliary cirrhosis)8-10 坏死后性肝硬化(post-necrotic cirrhosis)8-11 息肉型胃癌(polypoid type of gastric carcinoma)8-12 溃疡型胃癌(ulcerative type of gastric carcinoma)8-13 浸润型胃癌(infiltrating type of gastric carcinoma)8-14 食管癌(carcinoma of the esophagus)8-15 巨块型肝癌(unifocal large mass type of primary carcinoma of the liver)8-16 结节型肝癌(multifocal type with numerous nodules of primary carcinoma of the liver)8-17 胰腺癌(carcinoma of the pancreas)8-18 结肠癌(carcinoma of colon)8-19 急性胆囊炎(acute cholecystitis)8-20 慢性胆囊炎(chronic cholecystitis)8-21 慢性萎缩性胃炎(chronic atrophic gastritis)8-22 慢性胃溃疡(chronic gastric ulcer)8-23 急性阑尾炎(acute appendicitis)8-24 慢性阑尾炎(chronic appendicitis)8-25 门脉性肝硬化(portal cirrhosis)8-26 胆汁性肝硬化(biliary cirrhosis)8-27 急性(普通型)肝炎( acute hepatitis)8-28 急性重症肝炎(acute severe hepatitis)8-29 亚急性重症肝炎(subacute severe hepatitis)8-30 急性胆囊炎(acute cholecystitis)8-31 胃粘液腺癌(mucinous gland gastric carcinoma)8-32 食管癌(carcinoma of the esophagus)8-33 肝细胞癌(hepatocellular carcinoma)9-01 霍奇金淋巴瘤(Hodgkin’s lymphoma)9-02非霍奇金淋巴瘤 (non-Hodgkin’s lymphoma)9-03非霍奇金淋巴瘤之淋巴结 (lymph node of non-Hodgkin’s lymphoma )9-04急、慢性髓母细胞性白血病 (actue/chronic myelogenous leukemia)9-05 慢性粒细胞白血病之脾 (spleen of chronic myelogenous leukemia)9-06霍奇金淋巴瘤(Hodgkin’s lymphoma)9-07 非霍奇金淋巴瘤—小细胞淋巴瘤(non-Hodgkin’s lymphoma)9-08急性髓母细胞白血病之肝脏(liver of acute myeloblastic leukemia )9-09急性髓母细胞性白血病(血图片)(acute myeloblastic leukemia)10-01狼疮性肾炎(lupus nephritis)10-02 心脏移植(heart transplantation)11-01急性弥漫性增生性肾小球肾炎(acute diffuse proliferative glomerulonephritis) 11-02新月体性肾小球肾炎(crescentic glomerulonephritis)11-03慢性肾小球肾炎(chronic glomerulonephritis)11-04急性肾盂肾炎(acute pyelonephritis)11-05慢性肾盂肾炎(chronic pyelonephritis)11-06肾细胞癌(renal cell carcinoma)11-07膀胱乳头状癌(papillary carcinoma of bladder)11-08肾母细胞瘤(nephroblastoma)11-09急性弥漫性增生性肾小球肾炎(acute diffuse proliferative glomerulonephritis)11-10 新月体性肾小球肾炎(crescentic glomerulonephritis)11-11 轻微病变性肾小球肾炎(minimal change glomerulonephritis)11-12 膜性肾小球肾炎(membranous glomerulonephritis)11-13 膜性增生性肾小球肾炎(membranoproliferative glomerulonephritis)11-14 慢性肾小球肾炎(chronic glomerulonephritis)11-15 急性肾盂肾炎(acute pyelonephritis)11-16 慢性肾盂肾炎(chronic pyelonephritis)11-17 肾透明细胞癌(clear cell renal carcinoma)11-18膀胱移行细胞癌(transitional cell carcinoma of the bladder)12-01 子宫颈癌(外生菜花型)(cervical carcinoma)12-02 子宫内膜腺癌(endometrial adenocarcinoma)12-03 子宫平滑肌瘤(leiomyoma of the uterus)12-04 完全性葡萄胎(hydatidiform mole)12-05 绒毛膜癌(choriocarcinoma)12-06 卵巢粘液性囊腺瘤(mucinous cystadenoma of ovary)12-07 卵巢浆液性乳头状囊腺瘤(serous cystadenoma of ovary)12-08 乳腺纤维腺瘤(fibroadenoma of the breast)12-09 乳腺癌(carcinoma of the breast)12-10 炎症性乳腺癌(inflammatory carcinoma of the breast)12-11 慢性子宫颈炎(chronic cervicitis)12-12 子宫颈浸润性鳞状细胞癌(invasive squamous cell carcinoma)12-13 葡萄胎(hydatidiform mole)12-14 绒毛膜癌(choriocarcinoma)12-15 卵巢浆液性囊腺瘤(serous cystadenoma of ovary)12-16 乳腺浸润性导管癌(invasive ductal carcinoma of the breast)13-01 单纯性甲状腺肿(simple goiter)13-02 毒性甲状腺肿(toxic goiter)13-03 甲状腺瘤(thyroid adenoma)13-04 甲状腺癌(carcinoma of thyroid)13-05胶样甲状腺肿(colloid goiter)13-06 毒性甲状腺肿(toxic goiter)13-07 甲状腺滤泡性腺瘤(follicular adenoma of thyroid)13-08 甲状腺乳头状癌(papillary carcinoma of thyroid)13-09 甲状腺髓样癌(medullary carcinoma of thyroid)14-01 流行性脑脊髓膜炎(epidemic cerebrospinal meningitis)14-02 流行性乙型脑炎(epidemic encephalitis B)14-3 胶质瘤(glioma)14-03流行性脑脊髓膜炎 (epidemic cerebrospinal meningitis)14-04 流行性乙型脑炎(epidemic encephalitis B)15-01原发性肺结核病 (primary pulmonary tuberculosis)15-02支气管淋巴结结核病15-03肺粟粒性结核病 (pulmonary miliary tuberculosis)15-04全身粟粒性结核病( systemic miliary tuberculosis)15-05局灶型肺结核15-06浸润型肺结核(Infiltrative pulmonary tuberculosis)15-07干酪样肺炎(caseous pneumonia)15-8急性空洞性肺结核15-9慢性纤维空洞型肺结核(chronic fibro-cavitative pulmonary tuberculosis )15-10肺结核球 (tuberculoma)15-11结核性胸膜炎 (tuberculous pleuritis)15-12肠结核病(溃疡型)(intestinal tuberculosis,ulcer)15-13肾结核病 (t uberculosis of kidney)15-14结核性脑膜炎(tubercular meningitis)15-15 脊髓结核 (tuberculosis of spine)15-16 关节结核(tuberculosis of joint)15-17附睾结核 (tuberculosis of epididymis)15-18腹膜及肠系膜淋巴结结核 (tuberculosis of epididymis)15-19肠伤寒各期之回肠 (typhoid fever)15-20细菌性痢疾之结肠 (colon of bacillary dysentery)15-21中毒型细菌性痢疾 (toxic type bacillary dysentery)15-22流行性出血热之心(heart of epidemic hemorrhagic fever)15-23流行出血热之肾(kidney of epidemic hemorrhagic fever)15-24白色念珠菌病之食管(esophagus of white candidiasis )15-25肺粟粒性结核病(以增生为主)(proliferative pulmonary tuberculosis) 15-26肺粟粒性结核病(以渗出为主) (exudative pulmonary tuberculosis) 15-27肺结核球(tuberculosis)15-28肠结核(溃疡型)(intestinal tuberculosis)15-29结核性脑膜炎(tubercular meningitis)15-30肠伤寒(typhoid fever)15-31细菌性痢疾 (bacillary dysentery)15-32 尖锐湿疣(condyloma acuminatum)15-33肺曲菌病 (aspergillosis of lung)15-34流行性出血热肾脏(kidney of epidemic hemorrhagic fever)16-01 结肠阿米巴病(intestinal amoebiasis)16-02 阿米巴肝脓肿(amoebic liver abscess)16-03 肠阿米巴病(intestinal amoebiasis)16-04 血吸虫病(schistosomiasis)16-05 肺吸虫病(parogonimiasis)。
心脏移植术后免疫诱导预防排斥反应的系统评价

心脏移植术后免疫诱导预防排斥反应的系统评价李扬侯震童惟依邓靖飞杨渊银中国医学科学院医学信息研究所,北京100005[摘要]目的系统评价心脏移植术后免疫诱导预防排斥反应的疗效。
方法检索PubMed、Embase、Cochrane Library、中国生物医学文献数据库,收集心脏移植诱导治疗包括抗胸腺细胞免疫球蛋白渊ATG)、巴利昔单抗(BAS)等相关文献,时间从建库至2020年3月,主要结果为1年排斥反应率,运用RevMan5.4软件进行分析。
结果最终纳入12项研究,共38764例。
结果显示BAS组1年排斥反应率高于ATG组,差异有统计学意义(OR=2.03,95%CI:1.78-2.32,P<0.01)遥ATG组、BAS组和无诱导组1年排斥反应率比较,差异无统计学意义(P>0.05)。
阿仑单抗组1年排斥反应率低于无诱导组,差异有统计学意义(P<0.05)。
结论心脏移植后使用ATG预防1年排斥反应效果优于使用BASo[关键词]心脏移植;诱导治疗;排斥;感染;生物制剂[中图分类号]R556.5[文献标识码]A[文章编号]1673-7210(2020)12(b)-0072-04 Systematic evaluation of the effect of immune induction after heart transplantation on the prevention of rejectionLI Yang HOU Zhen TONG Weiyi DENG Jingfei YANG Yuan kInsLiLuLe of Medcial InformaLion,China Academy of Medical Sciences,Beijing100005,China[Abstract]Objective To systematically evaluaLe Lhe effecL of immune induction on preventing rejection afLer hearL LransplanLaLion.Methods PubMed,Embase,Cochrane Library,Chinese Biomedical LiLeraLure DaLabase were searched, and relaLed liLeraLure on inducLion Lherapy of hearL LransplanLaLion were collecLed,including anLiLhymocyLe immunoglobulin(ATG),basiliximab(BAS).The Lime from Lhe establishment of Lhe database Lo March2020,Lhe main resulL was Lhe one-year rejection raLe,and RevMan5.4software was used for analysis.Results Finally,a LoLal of12sLudies were included,wiLh a LoLal of38764cases.The resulLs showed LhaL Lhe one-year rejection raLe of Lhe BAS group was higher Lhan LhaL of Lhe ATG group,and Lhe difference was sLaLisLically significanL(OR=2.03,95%CI:1.78-2.32,P<0.01).There was no sLaLisLically significanL difference in Lhe one-year rejection raLe beLween Lhe ATG group,Lhe BAS group and Lhe non-inducLion group(P>0.05).The one-year rejection raLe of Lhe AlemLuzumab group was lower Lhan LhaL of Lhe no-inducLion group,and Lhe difference was sLaLisLically significanL(P<0.05).Conclusion AfLer hearL LransplanLa-Lion,Lhe effecL on preventing one-year rejection of ATG is beLLer Lhan LhaL of Lhe BAS.[Key words]HearL LransplanLaLion;InducLion Lherapy;RejecLion;InfecLion;Biological agenLs免疫诱导治疗是在器官移植排斥反应风险最高时发挥高强度免疫抑制[1],自诞生之日起,预防性诱导治疗能否更好地预防免疫排斥反应就备受争议。
标准原位心脏移植术

标准原位心脏移植术近似词条心脏移植术SOTH护理院基本标准(2011版)医疗事故分级标准(试行)医疗器械标准管理办法(试行)血液净化标准操作规程(2010 版)卫生部营养标准专业委员会成立三级综合医院评审标准(2011年版)助理全科医生培训标准(试行)>>更多相关词条赞助商链接目录1. 拼音2. 英文参考3. 手术名称4. 别名5. 分类6. ICD编码7. 概述8. 适应症9. 禁忌症10. 供体的选择11. 术前准备12. 麻醉和体位13. 手术步骤1. 1.供心的修剪2. 2.切除受体病变心脏3. 3.植入供体心脏14. 术中注意要点15. 术后处理1. 1.常规处理2. 2.血流动力学支持3. 3.预防感染4. 4.免疫排斥反应的监测及治疗16. 相关文献[返回]拼音shùbiāo zhǔn yuán wèi xīn zāng yí z hí [返回]英文参考standard orthotopic cardiac transplantation[返回]手术名称标准原位心脏移植术[返回]别名标准原位心脏移植手术;SOTH[返回]分类心血管外科/心脏移植/原位心脏移植[返回]ICD编码37.5101[返回]概述原位心脏移植是将受体病变心脏切除后在原位植入供体的心脏。
按照右心连接方法不同又分为标准原位心脏移植法和改良原位心脏移植法。
[返回]适应症标准原位心脏移植术适用于:心脏移植适用于内科治疗无效、顽固性心力衰竭,伴或不伴有恶性心律失常的终末期心脏病,而其他脏器无不可逆性损害的病人。
心功能为Ⅳ级,预期生存时间<12个月。
早年做心脏移植要求病人年龄在55岁以下,现已扩大年龄范围,从1岁以内婴幼儿到70岁老人均可手术。
1.心肌病各种心肌病包括扩张型心肌病、慢型克山病及限制型心肌病等,约占全部病例的50%,是心脏移植的主要适应证。
2.冠心病由于严重的多支冠状动脉病变或广泛性心肌梗死引起顽固性心力衰竭及心律失常为主要特征的缺血性心肌病,约占心脏移植的40%。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Circulation. 1995;91:1706-1713.)© 1995 American Heart Association, Inc.Occult and Frequent Transmission of Atherosclerotic Coronary Disease With Cardiac TransplantationInsights From Intravascular UltrasoundE. Murat Tuzcu, MD; Robert E. Hobbs, MD; Gustavo Rincon, MD; Corinne Bott-Silverman, MD; Anthony C. De Franco, MD; Killian Robinson, MD; Patrick M. McCarthy, MD; Robert W. Stewart, MD; Skip Guyer, RCPT; Steven E. Nissen, MDFrom the Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, Ohio.Correspondence to E. Murat Tuzcu, MD, Department of Cardiology, The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F-25, Cleveland, OH 44195-5066.AbstractBackground Transplant coronary artery disease is a major cause of morbidity and mortality after cardiac transplantation. However,limited data exist regarding the potential contribution of coronary atherosclerosis in the donor heart to cardiac-allograft vasculopathy.Methods and Results We performed quantitative coronary angiography and intravascular ultrasound imaging in 50 of 62 consecutive heart-transplant recipients (40 men, 10 women, mean age, 53±9years) 4.6±2.6 weeks after transplantation. The donor population consisted of 30 men and 20 women (mean age, 32±12 years). Ultrasound imaging visualized all three coronary arteries in 22 patients, two coronary arteries in 23, and one coronary artery in 5. Ultrasound imaging detected coronary atherosclerosis (intimal thickness 0.5 mm) in28 patients (56%). However, the angiography was abnormal in only 13 patients (26%). The sensitivity and specificity of coronary angiography were 43% and 95%, respectively. With ultrasound, the average atherosclerotic plaque thickness was 1.3±0.6 mm and the cross-sectional area narrowing was 34±16%. Atherosclerotic involvement frequently was focal (85%), eccentric (mean eccentricity index,87±8), and near arterial bifurcations. Donors of the transplant recipients with coronary atherosclerosis were older than those without atherosclerosis (37±12 versus 25±10 years, P=.001). Maximal intimal thickness correlated with donor age (r=.54, P=.0001). Multivariate analysis demonstrated that donor age (P=.0001), male sex of donor (P=.0006), and recipient age (P=.03) were independent predictors of atherosclerosis.Conclusions Coronary atherosclerosis is frequently but inadvertently transmitted by means of cardiac transplantation from the donor to the recipient. Long-term outcomes of donor-transmitted coronary artery disease will require further evaluation.Key Words:transplantation • coronary disease • ultrasonicsIntroductionSurvival rates after cardiac transplantation have improved steadily during the past 2 decades. Presently, 1-year survival rates average 80% to 90% at most active centers.12 After the first year after transplantation, cardiac-allograft vasculopathy represents the principal cause of death.34Necropsy examinations have described cardiac-allograft vasculopathy as a diffuse, obliterative process characterized by concentric intimal proliferation.567 Prior reports89 have emphasized that the predominant mechanism for genesis of transplant vasculopathy is immune injury with resulting intimal hyperplasia. Transplant coronary disease eventually results in multiple myocardial infarctions, which lead to accelerated graft failure or sudden cardiac death.Both postmortem and intravascular ultrasound imaging studies have demonstrated that angiography underestimates the extent and severity of transplant vasculopathy.10111213 Although most centers perform routine surveillance angiography at annual catheterization, this screening process often fails to detect coronary disease. There is limited information regarding the prevalence of atherosclerosis in donor hearts and its effect on coronary disease after transplantation. Accordingly, we examined this phenomenon by performing quantitative coronary angiography and intravascular ultrasound imaging soon after cardiac transplantation. We sought to determine the frequency and morphological patterns of atherosclerosis transmitted from heart donors to recipients.MethodsPatient PopulationThe study group consisted of patients who underwent cardiac transplantation between December 31, 1992, and February 14, 1994.Patients who were ineligible for cardiac catheterization, who died during hospitalization, or who did not give informed consent were excluded. The study protocol was approved by the Institutional Review Board of The Cleveland Clinic Foundation. Cardiac CatheterizationRecipients were studied within 2 months after cardiac transplantation.All patients underwent right and left heart catheterization,endomyocardial biopsy, coronary angiography, and intravascular ultrasound imaging. After nitroglycerin was administered sublingually,coronary arteriography was performed with large-lumen 7F coronary-guiding catheters.14 Multiple angiographic views were obtained for optimal visualization of the coronary arteries.Coronary Intravascular Ultrasound ImagingIntravascular ultrasound imaging was performed on the recipients with a 30 MHz 3.5F ultrasound catheter (Boston Scientific) interfaced with a dedicated scanner (Hewlett Packard). The ultrasound catheter consisted of a 135-cm-long monorail device with a transducer enclosed in an acoustically transparent housing that was 20 mm from the tip. A driveshaft cable rotated the transducer at 1800 rpm to generate a 360° imaging plane angled 15° forward from perpendicular to the long axis of the catheter. The axial resolution of the imaging system, which varied with distance, averaged80 to 100 µm, whereas lateral resolution ranged from 150to 200 µm. This device generated ultrasound images at30 frames per second, and continuously recorded these images on 1/2-in Super-VHS videotape.After coronary angiography, recipients were given 3000 to 5000U IV heparin before being examined by intravascular ultrasound imaging. The operator used fluoroscopic guidance to place a0.014-in high-torque angioplasty guide wire at a distal location in the target vessel. The ultrasound catheter was placed over the guide wire at the most distal site in the coronary artery to which it could be advanced safely. The ultrasound catheter was then withdrawn gradually from this distal location during continuous imaging. At sites of atherosclerosis and adjacent normal segments, pullback was paused for identification. A cineangiogram and an audio recordingdocumented the location of the imaging probe and its proximity to branches and other anatomic landmarks at each of these sites. Proximal, mid, and distal segments of the three major epicardial coronary arteries, defined according to Coronary Artery Surgery Study (CASS) classifications, were targeted for imaging.15Ultrasound Imaging AnalysisThe intravascular ultrasound images were analyzed by blinded observers in the intravascular ultrasound imaging core laboratory. For each site examined, a short segment (10 to 20 seconds) of videotape was digitized at 30 frames per second into a 640x480-pixel matrix image with a 24-bit gray scale. The full-motion sequence was examined frame by frame to select for analysis the image with the most atherosclerosis.The selected frames were used to make the following measurements:(1) Maximal intimal thickness was measured as the greatest distance from the intimal leading edge to media-adventitia border, (2)minimal intimal thickness as the shortest distance from the intimal leading edge to media-adventitia border, (3) minimal luminal diameter as the shortest distance between opposing intimal leading edges, (4) lumen area as the area within the boundaries of the intimal leading edge, (5) vessel area as the area within the media-adventitia border, and (6) plaque cross-sectional area as the difference between vessel and lumen areas. Also,a relative measure of ultrasound percent area reduction was computed as follows: lumen area divided by vessel area multiplied by100 (Fig 1).View larger version(88K):[in this window] [in a new window]Figure 1. Measurements of lumen and vessel wall dimensions in an ultrasound image.Patients were divided into atherosclerotic and nonatherosclerotic subgroups that were stratified by the maximal intimal thickness of all examined sites. The atherosclerotic group included patients with intimal thickness 0.5 mm, whereas the nonatherosclerotic group included those with a maximal intimal thickness <0.5 mm. The distribution pattern of atherosclerosis was assessed longitudinally and circumferentially.Diffuse disease was defined as intimal thickening of the entire length of the artery, whereas focal disease consisted of intimal thickening of isolated sites. The circumferential distribution of atherosclerotic plaque was determined as follows.Angiographic AnalysisCineangiograms were reviewed in the core cineangiography laboratory by an experienced angiographer blinded to the results of the ultrasound imaging study. The angiograms were projected onto a screen at a fixed distance with a rear-projection system (Tagarno 35AX).For each coronary artery, the CASS segment classification system was used to identify the most distal site imaged by ultrasound.Stenosis severity at sites showing any luminal narrowing was measured with an Atari digital caliper system (Sandhill Scientific,Inc). For each identifiable lesion, the operator determined vessel diameter at the stenosis and at an adjacent angiographically normal reference site to quantify percent diameter stenosis.Statistical AnalysisNormally distributed data were reported as mean±SD. 2-test or Fisher's exact test was used to find significant associations between categorical variables. An unpaired t test was used to test for differences between the mean values for continuous variables in subgroups. Pearson's correlations were used to test for relations between continuous variables. Stepwise linear regression was used to determine which factors (age, sex, cytomegalovirus[CMV] virus titers for donors and recipients, ischemic time for the donor heart, rejection episodes, donor family history for coronary artery disease, smoking history, and hypertension) were significantly related to atherosclerosis after adjustment for other significant factors. A value of P.05 was considered statistically significant.ResultsPatient CharacteristicsSixty-two adult patients underwent cardiac transplantation between December30, 1992, and February 14, 1994. All but 5 underwent cardiac catheterization within 2 months after transplantation. The 5 patients not examined included 4 who died soon after the operation (1 from multiorgan failure, 1 from cerebral hemorrhage, 1 from sepsis, and 1 from aortic rupture). One additional patient had severe medical problems precluding catheterization. Of the remaining 57 patients, 50 underwent successful intravascular ultrasound imaging. The 7 patients who did not undergo imaging included 3 patients with scheduling constraints,2 with angiographically evident severe coronary artery disease,and 2 who experienced technical problems related to the equipment.The 50 cardiac transplant recipients were studied an average of4.6±2.6 weeks after the operation. This cohort included40 men and 10 women with a mean age of 53±9 years. Of the 50 recipients, 40 had positive CMV titers and 14 had experienced at least one episode of rejection requiring treatment before catheterization (Table 1).ischemic time for the donor heart, defined as the interval between removal of the donor heart and transplantation, averaged 134±40 minutes. Of the 50 donors, 31 had positive CMV titers. The medical and social histories of donors were not complete in some cases. Twenty-four of 42 donors were known smokers, 4 of 42 were hypertensive,and 3 of 24 had a family history of coronary artery disease.Because most donors were identified after major trauma, reliable basal lipid levels were not available (Table 1).All three major epicardial coronary arteries were imaged successfully in 22 patients, two arteries were imaged in 23 patients, and only one vessel was imaged in 5 patients (Table 2). Thus, 117 first-order epicardial vessels were examined in the 50 patients.The right coronary artery was not imaged in 19 patients, the left circumflex in 12, and the left anterior descending in 2. Arteries were not imaged in 14 patients because of tortuosity, in 8 because of a small-caliber vessel, in 5 because of a nondominant right coronary artery, in 4 because of coronary spasm, and in 2 for technical reasons. Of the 450 CASS segments targeted, 255 (112proximal, 96 mid, and 47 distal) were imaged (Table 2), with no complications other than reversible coronary spasm.In 22 patients, the appearance of the coronary arteries with ultrasound imaging was normal, with maximal intimal thickness <0.5 mm (Fig2). By applying a criterion for atherosclerosis requiring an intimal thickness 0.5 mm, it was determined that 28 patients(56%) had unequivocal evidence of disease (Fig 3). In this subgroup,maximal intimal thickness averaged 1.3±0.6 mm; mean luminal diameter, 3.4±1.1 mm; and average luminal cross-sectional area, 11.8±5.8 mm2. The plaque cross-sectional area averaged5.5±2.4 mm2, which represented a cross-sectional area reduction of 34±16%. Thus, a significant amount of atherosclerosis was detected in more than half the recipients studied early after transplantation.View larger version (33K): [in this window][in a new window]Figure 3.thickness in 50 cardiac transplantation patients.Atherosclerotic plaque involvement was focal rather than diffuse in24 of 28 patients. In patients with focal disease, plaque was observed most frequently near arterial bifurcation sites (Fig 4). In14 patients (50%), atherosclerotic involvement was evident near the left anterior descending–circumflex artery bifurcation.Of the 14 patients, 9 had plaque on the left anterior descending side of the bifurcation, 3 on the circumflex side, and 2 on both sides. In all cases, the plaque was on the wall opposite the arterial carina of the branching vessel. An atheroma was found near the left anterior descending–diagonal artery bifurcation in 8 patients, and plaque was seen at the circumflex-obtuse marginal bifurcation in 2 patients. One patient had a plaque in the right coronary artery at the site of bifurcation in a right ventricular branch.These patterns served to emphasize the focal nature of plaque distribution in patients studied early after transplantation.Of the 28 patients with atherosclerosis, 19 had an atherosclerotic plaque in more than one arterial segment.in these 28 patients (Fig 5mean eccentricity index was 87±8%,which demonstrated that nearly all of the plaque was located on one side of the artery. Of the 28 recipients who had atherosclerotic involvement,the eccentricity index was >50% in every patient and was >75%in 26 of 28. In all cases, the surfaces of the coronary plaques were smooth. There was no evidence of ulcerated plaque or plaque dissection in any of the imaged arteries. Calcified elements occurred in the plaques of 9 of 28 patients.View largerversion (85K):[in this window][in a newwindow]Figure 5. Top, Angiogram of the left coronary artery in the right anterioroblique projection showing mild luminal narrowing. Black arrowindicates the site of intravascular ultrasound imaging. Bottom, Two-dimensional intravascular ultrasound image revealing a large eccentricplaque in the proximal circumflex artery (black arrow).Risk Factors for AtherosclerosisDonor age and recipient age were the only variables found to be significantly different between the atherosclerotic and nonatherosclerotic groups by univariate analysis. Although all donorswere relatively young, the donors for recipients who had atherosclerotic involvement were significantly older (37±12 versus 25±10 years,P=.0003, Table 1). Linear-regression analysis revealed a moderate correlation between maximal plaque thickness and donor age (r=.54,P=.0001, Fig 6). A less-significant difference existed between the two subgroups with regard to recipient age (55±9versus 49±10 years, P=.02). Univariate analysis demonstrated no significant differences for the remaining variables, including donor hypertension, smoking history, family history of coronary disease, rejection episodes, donor and recipient CMV titers,time between transplantation and imaging, ischemic time, and number of vessels and segments imaged.View larger version (20K):Scatterplot showing correlation between donor age and intimal thickness. indicates male donors; ,and recipient age (P=.03) were independent predictors of atherosclerosis. There was no correlation between recipient and donor ages (r=.11, P=.43) to explain these findings. However, when plaque thickness was analyzed with donor age and recipient age as categorical variables (age <30 or 30) rather than as continuous factors, only donor age (P=.0001) and donor sex were significant factors for predicting atherosclerosis (P=.008,Table 3).Quantitative coronary arteriography revealed completely normal coronary arteries in 37 of 50 patients (74%). In the other 13 patients,angiographic stenosis ranged from 10% to 38% (22±7%), and ultrasound imaging confirmed the presence of a plaque in abnormal segments in 12 of these patients. Thus, coronary angiography detected atherosclerosis in only 12 of the 28 patients (43% sensitivity) who had atherosclerosis but correctly identified21 of 22 normal cases (95% specificity, Fig 7). In 3 patients,angiography detected more than one lesion; some of these lesions were in segments not imaged by ultrasound. However, in all 3of these patients, ultrasound imaging identified atherosclerosis in more than one segment.View larger version (166K): [in this window][in a new window]Figure 7. A, Arteriogram of the left coronary artery in theright anterior oblique projection. Black arrow indicatesimaging site shown in B; white arrow, imaging site shownin D. B, intravascular ultrasound image of the proximalcircumflex artery. Despite a large eccentric plaque, a largecircular lumen similar to that in D is preserved because ofremodeling. C, Left coronary angiogram in the left anterioroblique projection. Black arrow indicates imaging siteshown in B; white arrow, imaging site of proximalcircumflex artery shown in D. D, intravascular ultrasoundimage at another site in the proximal circumflex arteryshowing normal arterial morphology.DiscussionCoronary artery disease represents the major cause of late death in patients after cardiac transplantation. Cardiac-allograft vasculopathy has been reported1617 to be an immunologic process in which intimal injury leads to proliferation and, eventually, to arterial obstruction. The present study, which uses quantitative coronary arteriography and a new high-resolution intravascular ultrasound imaging device, demonstrates an alternative cause. In the first few weeks after transplantation, comprehensive imaging of multiple major epicardial coronary arterial segments revealed typical atherosclerotic plaque in 56% of recipients. Thus, unequivocal evidence of transmission of atherosclerosis from the donor to recipient was present in more than one half of the recipients.These findings are particularly striking when one considers the conservative definition that is used in the present study to classify the presence or absence of atherosclerosis. Although the normal intima in young subjects consists of only a few cell layers, limited data are available to describe the range of normal intimal thickness in adults. In a necropsy study, normal intimal thickness averaged 0.21 mm (0.10 to 0.28 mm) in 21-to 25-year-old men and 0.25 mm (0.18 to 0.35 mm) in 36- to 40-year-old men.18 In a comparative ultrasound-histology study, patients with no known coronary artery disease had intimal thicknesses averaging 0.24±0.11 mm.19 An in vivo ultrasound imaging study20 reported mean intimal thickness in a "normal" population as 0.18 mm, with 95% confidence intervals of 0.06 and 0.30 mm.However, in normal subjects, intimal thickness and echogenicity increases with age. Thus, in very young subjects, a distinct laminar structure often is not evident by intravascular ultrasound.1920 To avoid potential controversy regarding interpretation of this study, we used a high threshold (0.5 mm) for abnormal intimal thickness. This value represents intimal thicknesses at least three SDs greater than any published range of normal values.The pattern of atherosclerotic plaque in these patients was typical of atherosclerosis and distinctly different from immune-mediated transplant vasculopathy. Most atheromas were highly eccentric, with >87%of plaque on one side of the vessel. In addition, the lesions showed apredilection for sites of major bifurcations. Experimental studies suggest that low shear stress along the non–flow-dividing wall might be an important localizing force, in contrast to the high shear stress along the flow-dividing wall (carina at vessel bifurcation).21 The morphological characteristics of the plaques are typical of conventional atherosclerosis and dissimilar to vasculopathy as described in the transplant population.22Indeed, features characteristic of transplant vasculopathy, particularly diffuse, concentric intimal thickening, were absent in our study group. Thus, it is evident that the atherosclerotic changes were present in the donor hearts and transmitted to the recipients at cardiac transplantation.This study highlights the limitations of standard coronary arteriography for detecting early transplant coronary disease. Quantitative coronary angiography was relatively insensitive, revealing less than half the lesions identified by intravascular ultrasound imaging.An important explanation for the discrepancy between angiography and ultrasound imaging is provided by the anatomic pattern of early atherosclerosis. As originally described by Glagov et al,23early coronary disease is characterized by remodeling of the coronary artery, which protects against luminal encroachment of the atherosclerotic plaque. Thus, segments with major intimal thickening retain a lumen size virtually identical to adjacent, uninvolved sites. In the absence of luminal narrowing, angiography fails to detect early disease.Few demographic characteristics were useful for predicting the likelihood of donor atherosclerosis. Multiple-regression analysis showed only donor age, recipient age, and donor sex to be independent predictors.The strongest predictor was donor age, which correlated significantly with intimal thickness. Although donor sex was not (univariately)associated with maximal intimal thickness, it became a significant factor after adjusting for donor age. It is not surprising that hearts from older men tended to have a higher prevalence of atherosclerosis,since age and male sex are well-known risk factors for coronary disease. It is more difficult to explain the unfavorable effect of recipient age on atherosclerosis early after transplantation. Acute rejection,2425 CMV infection,2627 and conventional risk factors have been suggested to be possible contributors to the development of chronic transplant coronary disease, but were not significant in this study. However, information about donor hypertension, smoking, family history, and hypercholesterolemia was incomplete. Thus, a full understanding of the relation between donor risk factors and early atherosclerosis cannot be stated conclusively.In a recent report from St Goar et al,28 with a larger (4.3F)earlier-generation intravascular ultrasound catheter, 25 patients were studied within 1 month of cardiac transplantation. Imaging was limited to segments extending from the ostium of the left main coronary artery to the midportion of the left anterior descending coronary artery. In 5 of 25 patients, there was eccentric intimal thickening>0.5 mm. The difference in the prevalence of atherosclerosis between the study by St Goar et al and ours is explained by several factors. In the present study, imaging was more extensive and an improved, low-profile 3.5F ultrasound probe was used.This permitted examination of multiple segments from major epicardial coronary arteries in 86% of patients. At least two of the three major coronary arteries were imaged in 90% of recipients. In addition,our study population was larger and donors were older (32±12 versus28±8 years old).These in vivo findings provide strong evidence as to the high prevalence of coronary atherosclerosis in young and middle-aged Americans.These findings are consistent with autopsy studies performed on large populations of trauma victims during the Korean and Vietnam wars.29 30 During the Korean War, atherosclerotic plaques with a wide range of stenoses (10% to 90%)were found in 117 of 300 young soldiers.29 Autopsy studies on American soldiers killed in Vietnam revealed that 45% had some coronary atherosclerosis.30In both necropsy studies, all thedeceased were men and mean subject age was 22 years old, whereas in our study, 40% of the donors were women and the mean donor age was 32±12 years.Furthermore, necropsy studies, which often examine explanted vessels not distended by physiological pressures, represent only estimations of the severity of coronary disease.This intravascular ultrasound imaging study provides direct in vivo evidence of occult, but rather extensive, atherosclerosis in a young and presumably healthy population. Without high-resolution intravascular ultrasound imaging, detection and quantification of atherosclerosis would not have been possible in living humans. Ultrasound imaging provides unique cross-sectional information that is analogous to pathology and that cannot be obtained in coronary arteries from any other imaging technique.The older age of the donor population in this study reflects an important trend in cardiac transplantation. The limited availability of suitable donors and the long waiting lists for transplantation have increased the use of older donors.31 However, the presence of atherosclerosis in more than 80% of our donors who are 30 years old indicates a potential hazard to this approach. The presence of coronary atherosclerosis in so many transplant recipients raises an important clinical question. Does disease transmitted from the donor increase the risk of accelerated transplant vasculopathy?This important clinical question cannot be answered until angiographic, ultrasound,and clinical follow-up studies determine the long-term prognostic significance of transmitted coronary disease.Reference1. Kriett JM, Kaye MP. The registry of the International Society for Heart and Lung Transplantation: eighth official report: 1991. J Heart Lung Transplant. 1991;10:491-498. [Medline][Order article via Infotrieve]2. Bourge RC, Naftel DC, Constanzo-Nordin MR, Kirklin JK, Young JB, Kubo SH, Olivari M-T, Kasper EK, The Transplant Cardiologists Research Database Group. Pretransplantation risk factors for death after heart transplantation: a multi-institutional study. J Heart Lung Transplant. 1993;12:549-562. [Medline][Order article via Infotrieve]3. Olivari MT, Homans DC, Wilson RF, Kubo SH, Ring WS. Coronary artery disease in cardiac transplant patients receiving triple drug immunosuppressive therapy. Circulation. 1989;80(suppl III):III-111-III-115.4. Schroeder JS, Hunt SA. Chest pain in heart transplant patients. N Engl J Med. 1991;324:1805-1807. [Medline][Order article via Infotrieve]5. Johnson DE, Gao SZ, Schroeder J, DeCampli WM, Billingham M. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant. 1989;8:349-359. [Medline][Order article via Infotrieve]6. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc. 1987;4:19-25.7. Billingham ME. Graft coronary disease: the lesions and the patients. Transplant Proc.1989;21:3665-3666. [Medline][Order article via Infotrieve]8. Uretsky BF, Kormos RL, Zerbe TR, Lee A, Tokarcyzk TR, Murali S, Reddy S, Dennys BG, Griffith BP, Hardesty RL, Armitage JM, Arena VC. Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. J Heart Transplant. 1992;11:S45-S50.9. Gao SZ, Schroeder JS, Hunt SA, Billingham ME, Valantine HA, Stinson EB. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol. 1989;64:1093-1096. [Medline][Order article via Infotrieve]10. O'Neill BJ, Pflugfelder PW, Single NR, Menkis AH, McKenzie FN, Kostuk WJ. Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three。